What Is Non-Small-Cell Lung Cancer (NSCLC)? Most people who have lung cancer have NSCLC. Although it's serious, treatment can sometimes stop it from getting worse. There are things you can do to ...

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer and carries a lower mortality risk than other forms. The most common risk factor for NSCLC is smoking cigarettes.

This overview provides a thorough review of current treatment approaches for first-line management of nononcogenic addicted non–small cell lung cancer. We also address pertinent clinical ...

Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was ...

Non-small-cell lung cancer (NSCLC) is the most common type of cancer affecting the lungs. The diverse types of NSCLC are characterized by cancer cells that grow and spread in different ways.

The five-year relative survival rate of small cell lung cancer—the odds that a cancer patient will live another five years compared to a non-patient—ranges from 7% to 30% depending on the ...

Among patients with advanced or metastatic non-small cell lung cancer (NSCLC) with actionable genomic alterations, encouraging and durable antitumor activity was observed during treatment with ...

Lung Squamous cell carcinoma (LSCC) represents the second most common non-small cell lung cancer. Although studies identified ...

Lung cancer is the leading cause of cancer deaths among both men and women. Small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) are the two main types of lung cancer. Most lung ...

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for 80-85% of all cases. It develops when abnormal lung cells grow uncontrollably, forming a tumor.

Adagrasib, a KRAS G12C inhibitor, irreversibly and selectively binds KRAS G12C, locking it in its inactive state. Adagrasib showed clinical activity and had an acceptable adverse-event profile in ...